1. Baskar, R., Lee, K.A., Yeo, R., Yeoh, K.-W., Baskar, R., and Phil, M. (2012). Cancer
and Radiation Therapy: Current Advances and Future Directions. Int. J. Med. Sci.
9, 193–199.
2. Rosenberg, S.A., and Restifo, N.P. (2015). Adoptive cell transfer as personalized
immunotherapy for human cancer. Science 348, 62–68.
3. Park, J.H., Geyer, M.B., and Brentjens, R.J. (2016). CD19-targeted CAR T-cell therapeutics for hematologic malignancies: Interpreting clinical outcomes to date.
Blood 127, 3312–3320.
4. Martino, M., Alati, C., Canale, F.A., Musuraca, G., Martinelli, G., and Cerchione, C.
(2021). A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute
Lymphoblastic Leukemia. Int. J. Mol. Sci. 22, 2150.
5. Tully, S., Feng, Z., Grindrod, K., McFarlane, T., Chan, K.K.W., and Wong, W.W.L.
(2019). Impact of Increasing Wait Times on Overall Mortality of Chimeric
Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event
Simulation Model. JCO Clin. Cancer Inform. 3, 1–9.
6. Caldwell, K.J., Gottschalk, S., and Talleur, A.C. (2020). Allogeneic CAR Cell
Therapy—More Than a Pipe Dream. Front. Immunol. 11, 618427.
7. Sadelain, M., Rivière, I., and Riddell, S. (2017). Therapeutic T cell engineering. Nature
545, 423–431.
8. Vormittag, P., Gunn, R., Ghorashian, S., and Veraitch, F.S. (2018). A guide to
manufacturing CAR T cell therapies. Curr. Opin. Biotechnol. 53, 164–181.
9. Iriguchi, S., and Kaneko, S. (2019). Toward the development of true “off-the-shelf”
synthetic T-cell immunotherapy. Cancer Sci. 110, 16–22.
10. Cutmore, L.C., and Marshall, J.F. (2021). Current Perspectives on the Use of off the
Shelf CAR-T/NK Cells for the Treatment of Cancer. Cancers 13, 1926.
11. Li, Y., Hermanson, D.L., Moriarity, B.S., and Kaufman, D.S. (2018). Human iPSCderived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance
Anti-Tumor Activity. Cell Stem Cell 23, 181–192.e5.
12. Arias, J., Yu, J., Varshney, M., Inzunza, J., and Nalvarte, I. (2021). Hematopoietic stem
cell- and induced pluripotent stem cell-derived CAR-NK cells as reliable cell-based
therapy solutions. Stem Cells Transl. Med. 10, 987–995.
13. Sachamitr, P., Hackett, S., and Fairchild, P.J. (2014). Induced pluripotent stem cells:
challenges and opportunities for cancer immunotherapy. Front. Immunol. 5,
176–179.
14. Iriguchi, S., Yasui, Y., Kawai, Y., Arima, S., Kunitomo, M., Sato, T., Ueda, T.,
Minagawa, A., Mishima, Y., Yanagawa, N., et al. (2021). A clinically applicable and
scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy. Nat. Commun. 12, 430–515.
15. Ueda, T., Shiina, S., Iriguchi, S., Terakura, S., Kawai, Y., Kabai, R., Sakamoto, S.,
Watanabe, A., Ohara, K., Wang, B., et al. (2023). Optimization of the proliferation
and persistency of CAR T cells derived from human induced pluripotent stem cells.
Nat. Biomed. Eng. 7, 24–37.
16. Wang, B., Iriguchi, S., Waseda, M., Ueda, N., Ueda, T., Xu, H., Minagawa, A.,
Ishikawa, A., Yano, H., Ishi, T., et al. (2021). Generation of hypoimmunogenic
T cells from genetically engineered allogeneic human induced pluripotent stem cells.
Nat. Biomed. Eng. 5, 429–440.
17. Dustin, M.L. (2014). The immunological synapse. Cancer Immunol. Res. 2,
1023–1033.
18. Nishimura, T., Kaneko, S., Kawana-Tachikawa, A., Tajima, Y., Goto, H., Zhu, D.,
Nakayama-Hosoya, K., Iriguchi, S., Uemura, Y., Shimizu, T., et al. (2013).
Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency
and redifferentiation. Cell Stem Cell 12, 114–126.
19. Maeda, T., Nagano, S., Ichise, H., Kataoka, K., Yamada, D., Ogawa, S., Koseki, H.,
Kitawaki, T., Kadowaki, N., Takaori-Kondo, A., et al. (2016). Regeneration of
CD8ab T cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity. Cancer Res. 76, 6839–6850.
20. Maeda, T., Nagano, S., Kashima, S., Terada, K., Agata, Y., Ichise, H., Ohtaka, M.,
Nakanishi, M., Fujiki, F., Sugiyama, H., et al. (2020). Regeneration of TumorAntigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with
Exogenous TCR Genes. Mol. Ther. Methods Clin. Dev. 19, 250–260.
21. Ochi, T., Nakatsugawa, M., Chamoto, K., Tanaka, S., Yamashita, Y., Guo, T.,
Fujiwara, H., Yasukawa, M., Butler, M.O., and Hirano, N. (2015). Optimization of
T-cell reactivity by exploiting TCR chain centricity for the purpose of safe and effective antitumor TCR gene therapy. Cancer Immunol. Res. 3, 1070–1081.
22. Rosati, E., Dowds, C.M., Liaskou, E., Henriksen, E.K.K., Karlsen, T.H., and Franke, A.
(2017). Overview of methodologies for T-cell receptor repertoire analysis. BMC
Biotechnol. 171 17, 61.
23. Smith-Garvin, J.E., Koretzky, G.A., and Jordan, M.S. (2009). T Cell Activation. Annu.
Rev. Immunol. 27, 591–619.
24. Kuhns, M.S., and Davis, M.M. (2007). Disruption of Extracellular Interactions
Impairs T Cell Receptor-CD3 Complex Stability and Signaling. Immunity 26,
357–369.
25. Natarajan, A., Nadarajah, V., Felsovalyi, K., Wang, W., Jeyachandran, V.R., Wasson,
R.A., Cardozo, T., Bracken, C., and Krogsgaard, M. (2016). Structural Model of the
Extracellular Assembly of the TCR-CD3 Complex. Cell Rep. 14, 2833–2845.
26. Krshnan, L., Park, S., Im, W., Call, M.J., and Call, M.E. (2016). A conserved ab transmembrane interface forms the core of a compact T-cell receptor-CD3 structure
within the membrane. Proc. Natl. Acad. Sci. USA 113, E6649–E6658.
27. Dong, D., Zheng, L., Lin, J., Zhang, B., Zhu, Y., Li, N., Xie, S., Wang, Y., Gao, N., and
Huang, Z. (2019). Structural basis of assembly of the human T cell receptor–CD3
complex. Nature 573, 546–552.
28. Newell, E.W., Ely, L.K., Kruse, A.C., Reay, P.A., Rodriguez, S.N., Lin, A.E., Kuhns,
M.S., Garcia, K.C., and Davis, M.M. (2011). Structural Basis of Specificity and
Cross-Reactivity in T Cell Receptors Specific for Cytochrome c–I-Ek. J. Immunol.
186, 5823–5832.
29. Okamoto, S., Amaishi, Y., Goto, Y., Ikeda, H., Fujiwara, H., Kuzushima, K.,
Yasukawa, M., Shiku, H., and Mineno, J. (2012). A promising vector for TCR gene
therapy: Differential effect of siRNA, 2A peptide, and disulfide bond on the introduced TCR expression. Mol. Ther. Nucleic Acids 1, e63.
30. Pageon, S.V., Tabarin, T., Yamamoto, Y., Ma, Y., Nicovich, P.R., Bridgeman, J.S.,
Cohnen, A., Benzing, C., Gao, Y., Crowther, M.D., et al. (2016). Functional role of
T-cell receptor nanoclusters in signal initiation and antigen discrimination. Proc.
Natl. Acad. Sci. USA 113, E5454–E5463.
31. Radtke, F., MacDonald, H.R., and Tacchini-Cottier, F. (2013). Regulation of innate
and adaptive immunity by Notch. Nat. Rev. Immunol. 13, 427–437.
32. Anderson, G., and Takahama, Y. (2012). Thymic epithelial cells: Working class
heroes for T cell development and repertoire selection. Trends Immunol. 33,
256–263.
33. Kondo, K., Ohigashi, I., and Takahama, Y. (2019). Thymus machinery for T-cell selection. Int. Immunol. 31, 119–125.
34. Kustikova, O.S., Wahlers, A., Kühlcke, K., Stähle, B., Zander, A.R., Baum, C., and
Fehse, B. (2003). Dose finding with retroviral vectors: correlation of retroviral vector
copy numbers in single cells with gene transfer efficiency in a cell population. Blood
102, 3934–3937.
Molecular Therapy: Methods & Clinical Development Vol. 31 December 2023
17
Molecular Therapy: Methods & Clinical Development
35. Mittelstadt, P.R., Monteiro, J.P., and Ashwell, J.D. (2012). Thymocyte responsiveness
to endogenous glucocorticoids is required for immunological fitness. J. Clin. Invest.
122, 2384–2394.
36. Minagawa, A., Yoshikawa, T., Yasukawa, M., Hotta, A., Kunitomo, M., Iriguchi, S.,
Takiguchi, M., Kassai, Y., Imai, E., Yasui, Y., et al. (2018). Enhancing T Cell
Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in
Cancer Immunotherapy. Cell Stem Cell 23, 850–858.e4.
37. Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H.,
Nakagawa, M., Tanabe, K., Tezuka, K.I., et al. (2011). A more efficient method to
generate integration-free human iPS cells. Nat. Methods 8, 409–412.
38. Kawai, Y., Kawana-Tachikawa, A., Kitayama, S., Ueda, T., Miki, S., Watanabe, A., and
Kaneko, S. (2021). Generation of highly proliferative rejuvenated cytotoxic T cell
clones through pluripotency reprogramming for adoptive immunotherapy. Mol.
Ther. 29, 3027–3041.
39. Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C.M., Quigley, M.F., Almeida, J.R.,
Gostick, E., Yu, Z., Carpenito, C., et al. (2011). A human memory T cell subset
with stem cell-like properties. Nat. Med. 17, 1290–1297.
40. Mariuzza, R.A., Agnihotri, P., and Orban, J. (2020). The structural basis of T-cell receptor (TCR) activation: An enduring enigma. J. Biol. Chem. 295, 914–925.
41. Courtney, A.H., Lo, W.L., and Weiss, A. (2018). TCR Signaling: Mechanisms of
Initiation and Propagation. Trends Biochem. Sci. 43, 108–123.
42. Kuhns, M.S., Davis, M.M., and Garcia, K.C. (2006). Deconstructing the form and
function of the TCR/CD3 complex. Immunity 24, 133–139.
43. Birnbaum, M.E., Berry, R., Hsiao, Y.S., Chen, Z., Shingu-Vazquez, M.A., Yu, X.,
Waghray, D., Fischer, S., McCluskey, J., Rossjohn, J., et al. (2014). Molecular architecture of the ab T cell receptor-CD3 complex. Proc. Natl. Acad. Sci. USA 111, 17576–
17581.
44. Schamel, W.W., Alarcon, B., and Minguet, S. (2019). The TCR is an allosterically
regulated macromolecular machinery changing its conformation while working.
Immunol. Rev. 291, 8–25.
45. Rafiq, S., Hackett, C.S., and Brentjens, R.J. (2020). Engineering strategies to overcome
the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147–167.
46. Oh, J., Warshaviak, D.T., Mkrtichyan, M., Munguia, M.L., Lin, A., Chai, F., Pigott, C.,
Kang, J., Gallo, M., and Kamb, A. (2019). Single variable domains from the T cell receptor b chain function as mono- and bifunctional CARs and TCRs. Sci. Rep. 9,
17291.
47. Themeli, M., Kloss, C.C., Ciriello, G., Fedorov, V.D., Perna, F., Gonen, M., and
Sadelain, M. (2013). Generation of tumor-targeted human T lymphocytes from
induced pluripotent stem cells for cancer therapy. Nat. Biotechnol. 31, 928–933.
48. Montel-Hagen, A., Seet, C.S., Li, S., Chick, B., Zhu, Y., Chang, P., Tsai, S., Sun, V.,
Lopez, S., Chen, H.C., et al. (2019). Organoid-Induced Differentiation of
Conventional T Cells from Human Pluripotent Stem Cells. Cell Stem Cell 24, 376–
389.e8.
49. Zhao, J., Song, Y., and Liu, D. (2019). Clinical trials of dual-target CAR T cells, donorderived CAR T cells, and universal CAR T cells for acute lymphoid leukemia.
J. Hematol. Oncol. 12, 17.
50. Jing, R., Scarfo, I., Najia, M.A., Lummertz da Rocha, E., Han, A., Sanborn, M.,
Bingham, T., Kubaczka, C., Jha, D.K., Falchetti, M., et al. (2022). EZH1 repression
generates mature iPSC-derived CAR T cells with enhanced antitumor activity. Cell
Stem Cell 29, 1181–1196.e6.
51. Keam, S.J. (2022). Valemetostat Tosilate: First Approval. Drugs 82, 1621–1627.
18
52. van der Stegen, S.J.C., Lindenbergh, P.L., Petrovic, R.M., Xie, H., Diop, M.P.,
Alexeeva, V., Shi, Y., Mansilla-Soto, J., Hamieh, M., Eyquem, J., et al. (2022).
Generation of T-cell-receptor-negative CD8ab-positive CAR T cells from T-cellderived induced pluripotent stem cells. Nat. Biomed. Eng. 6, 1284–1297.
53. Lanitis, E., Rota, G., Kosti, P., Ronet, C., Spill, A., Seijo, B., Romero, P., Dangaj, D.,
Coukos, G., and Irving, M. (2021). Optimized gene engineering of murine CAR-T
cells reveals the beneficial effects of IL-15 coexpression. J. Exp. Med. 218, e20192203.
54. Kokalaki, E., Ma, B., Ferrari, M., Grothier, T., Hazelton, W., Manzoor, S., Costu, E.,
Taylor, J., Bulek, A., Srivastava, S., et al. (2023). Dual targeting of CD19 and CD22
against B-ALL using a novel high-sensitivity aCD22 CAR. Mol. Ther. 31, I2089–
I2104.
55. Hua, J., Qian, W., Wu, X., Zhou, L., Yu, L., Chen, S., Zhang, J., and Qiu, H. (2020).
Sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells
for a pediatric Ph-like B-ALL patient that relapsed after CART-cell and HaploHSCT therapy: A case report and review of literature. OncoTargets Ther. 13,
2311–2317.
56. Albinger, N., Hartmann, J., and Ullrich, E. (2021). Current status and perspective of
CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. 28, 513–527.
57. Mailankody, S., Matous, J.V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O.O.,
Malik, S., Nath, R., Anwer, F., Cruz, J.C., et al. (2023). Allogeneic BCMA-targeting
CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial
interim results. Nat. Med. 2023 292 29, 422–429.
58. Chang, C., Van Der Stegen, S., Mili, M., Clarke, R., Lai, Y.-S., Witty, A., Lindenbergh,
P., Yang, B.-H., Husain, M., Shaked, H., et al. (2019). FT819: Translation of Off-theShelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical
Trial. Blood 134, 4434.
59. Park, J.H., Jain, N., Chen, A., McGuirk, J.P., Diaz, M., Valamehr, B., Chu, Y.-W., and
Castro, J.E. (2020). A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSCDerived TCR-Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/
Refractory B-Cell Malignancies. Blood 136, 15–16.
60. Osborn, M.J., Webber, B.R., Knipping, F., Lonetree, C.L., Tennis, N., DeFeo, A.P.,
McElroy, A.N., Starker, C.G., Lee, C., Merkel, S., et al. (2016). Evaluation of TCR
Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Mol.
Ther. 24, 570–581.
61. Legut, M., Dolton, G., Mian, A.A., Ottmann, O.G., and Sewell, A.K. (2018). CRISPRmediated TCR replacement generates superior anticancer transgenic T cells. Blood
131, 311–322.
62. Watanabe, K., Terakura, S., Martens, A.C., van Meerten, T., Uchiyama, S., Imai, M.,
Sakemura, R., Goto, T., Hanajiri, R., Imahashi, N., et al. (2015). Target Antigen
Density Governs the Efficacy of Anti–CD20-CD28-CD3 z Chimeric Antigen
Receptor–Modified Effector CD8+ T Cells. J. Immunol. 194, 911–920.
63. Kamiya, A., Kakinuma, S., Onodera, M., Miyajima, A., and Nakauchi, H. (2008).
Prospero-related homeobox 1 and liver receptor homolog 1 coordinated regulate
long-term proliferation of murine fetal hepatoblasts. Hepatology 48, 252–264.
64. Hanatani, T., and Takasu, N. (2021). CiRA iPSC seed stocks (CiRA’s iPSC Stock
Project). Stem Cell Res. 50, 102033.
65. Okita, K., Yamakawa, T., Matsumura, Y., Sato, Y., Amano, N., Watanabe, A.,
Goshima, N., and Yamanaka, S. (2013). An efficient nonviral method to generate
integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cell. 31, 458–466.
Molecular Therapy: Methods & Clinical Development Vol. 31 December 2023
...
論文の公開元へ
